Evaxion Biotech Q1 EPS $0.03 Beats $(0.56) Estimate, Sales $51.00K Beat $37.00K Estimate
Portfolio Pulse from Benzinga Newsdesk
Evaxion Biotech (NASDAQ:EVAX) reported Q1 earnings of $0.03 per share, significantly beating the analyst estimate of $(0.56). Sales also surpassed expectations, coming in at $51,000 compared to the $37,000 estimate.
May 28, 2024 | 12:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Evaxion Biotech reported Q1 earnings of $0.03 per share, beating the analyst estimate of $(0.56) by 105.36%. Sales also exceeded expectations, coming in at $51,000 compared to the $37,000 estimate.
The significant beat on both EPS and sales estimates is likely to positively impact the stock price in the short term. The earnings per share of $0.03 is a substantial improvement over the expected loss, indicating strong financial performance.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100